Amir J Guri1, Raquel Hontecillas, Josep Bassaganya-Riera. 1. Nutritional Immunology and Molecular Nutrition Laboratory, Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA.
Abstract
BACKGROUND & AIMS: Abscisic acid (ABA) is effective in preventing insulin resistance and obesity-related inflammation through a PPAR γ-dependent mechanism. The objective of this study was to assess the efficacy ABA in improving glucose homeostasis and suppress inflammation when administered in combination with rosiglitazone (Ros) and to determine whether PPAR γ activation by ABA is initiated via cAMP/protein kinase A (PKA) signaling. METHODS: Obese db/db mice were fed high-fat diets containing 0, 10, or 70 mg/kg Ros with and without racemic ABA (100 mg/kg) for 60 days. Glucose tolerance and fasting insulin levels were assessed at 6 and 8 weeks, respectively, and adipose tissue macrophage (ATM) infiltration was examined by flow cytometry. Gene expression was examined on white adipose tissue (WAT) and stromal vascular cells (SVCs) cultured with ABA, Ros, or an ABA/Ros combination. RESULTS: Both Ros and ABA improved glucose tolerance, and ABA decreased plasma insulin levels while having no effect on Ros-induced weight gain. ABA in combination with low-dose Ros (10 mg/kg; Roslo) synergistically inhibited ATM infiltration. Treatment of SVCs with Ros, ABA or ABA/Ros suppressed expression of the M1 marker CCL17. ABA and Ros synergistically increased PPAR γ activity and pretreatment with a cAMP-inhibitor or a PKA-inhibitor abrogated ABA-induced PPAR γ activation. CONCLUSIONS: ABA and Ros act synergistically to modulate PPAR γ activity and macrophage accumulation in WAT and ABA enhances PPAR γ activity through a membrane-initiated mechanism dependent on cAMP/PKA signaling.
BACKGROUND & AIMS:Abscisic acid (ABA) is effective in preventing insulin resistance and obesity-related inflammation through a PPAR γ-dependent mechanism. The objective of this study was to assess the efficacy ABA in improving glucose homeostasis and suppress inflammation when administered in combination with rosiglitazone (Ros) and to determine whether PPAR γ activation by ABA is initiated via cAMP/protein kinase A (PKA) signaling. METHODS:Obese db/db mice were fed high-fat diets containing 0, 10, or 70 mg/kg Ros with and without racemic ABA (100 mg/kg) for 60 days. Glucose tolerance and fasting insulin levels were assessed at 6 and 8 weeks, respectively, and adipose tissue macrophage (ATM) infiltration was examined by flow cytometry. Gene expression was examined on white adipose tissue (WAT) and stromal vascular cells (SVCs) cultured with ABA, Ros, or an ABA/Ros combination. RESULTS: Both Ros and ABA improved glucose tolerance, and ABA decreased plasma insulin levels while having no effect on Ros-induced weight gain. ABA in combination with low-dose Ros (10 mg/kg; Roslo) synergistically inhibited ATM infiltration. Treatment of SVCs with Ros, ABA or ABA/Ros suppressed expression of the M1 marker CCL17. ABA and Ros synergistically increased PPAR γ activity and pretreatment with a cAMP-inhibitor or a PKA-inhibitor abrogated ABA-induced PPAR γ activation. CONCLUSIONS:ABA and Ros act synergistically to modulate PPAR γ activity and macrophage accumulation in WAT and ABA enhances PPAR γ activity through a membrane-initiated mechanism dependent on cAMP/PKA signaling.
Authors: Richard W Nesto; David Bell; Robert O Bonow; Vivian Fonseca; Scott M Grundy; Edward S Horton; Martin Le Winter; Daniel Porte; Clay F Semenkovich; Sidney Smith; Lawrence H Young; Richard Kahn Journal: Circulation Date: 2003-12-09 Impact factor: 29.690
Authors: N Ouchi; S Kihara; Y Arita; Y Okamoto; K Maeda; H Kuriyama; K Hotta; M Nishida; M Takahashi; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa Journal: Circulation Date: 2000-09-12 Impact factor: 29.690
Authors: J Bassaganya-Riera; J Skoneczka; D G J Kingston; A Krishnan; S A Misyak; A J Guri; A Pereira; A B Carter; P Minorsky; R Tumarkin; R Hontecillas Journal: Curr Med Chem Date: 2010 Impact factor: 4.530
Authors: Stuart P Weisberg; Daniel McCann; Manisha Desai; Michael Rosenbaum; Rudolph L Leibel; Anthony W Ferrante Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: J Fruebis; T S Tsao; S Javorschi; D Ebbets-Reed; M R Erickson; F T Yen; B E Bihain; H F Lodish Journal: Proc Natl Acad Sci U S A Date: 2001-02-06 Impact factor: 11.205
Authors: Josep Bassaganya-Riera; Amir J Guri; Pinyi Lu; Montse Climent; Adria Carbo; Bruno W Sobral; William T Horne; Stephanie N Lewis; David R Bevan; Raquel Hontecillas Journal: J Biol Chem Date: 2010-11-18 Impact factor: 5.157
Authors: Pinyi Lu; Raquel Hontecillas; William T Horne; Adria Carbo; Monica Viladomiu; Mireia Pedragosa; David R Bevan; Stephanie N Lewis; Josep Bassaganya-Riera Journal: PLoS One Date: 2012-04-11 Impact factor: 3.240
Authors: Santina Bruzzone; Mirko Magnone; Elena Mannino; Giovanna Sociali; Laura Sturla; Chiara Fresia; Valeria Booz; Laura Emionite; Antonio De Flora; Elena Zocchi Journal: PLoS One Date: 2015-10-21 Impact factor: 3.240